PROMOMED DM LLC has paid the first coupon on the bonds

PROMOMED DM LLC has paid in full the first coupon yield on exchange-traded bonds of the 001P-01 series placed on the Moscow Stock Exchange in December 2020. The volume of payments amounted to 47.37 million rubles, which corresponds to a rate of 9.5% per annum.

Promomed allocated the funds received from the bond placement to the development and production of active pharmaceutical substances and ready-made dosage forms, as well as the construction of new laboratories and workshops. The company aims to expand its product portfolio through the development and production of the latest antiviral, antibacterial, endocrinological, neurological and oncological drugs.
"Investor interest in the company's bonds has been and remains high," says Peter Bely, Chairman of the Board of Directors of Promomed Group. Promomed is the only Russian pharmaceutical company with public debt instruments. We value the trust of investors, and we will continue to fulfill our financial obligations flawlessly and adhere to the best global corporate and financial practices."
Earlier, on March 4, 2021, PROMOMED DM LLC's exchange-traded bonds were included in the listing of the Innovation and investment Market sector of the Moscow Stock Exchange, which made these securities more attractive to a wide range of investors, exempting them from paying personal income tax (more details: https://promo-med.ru/04_03_21_moex.html ).
The debut placement of PROMOMED DM LLC's exchange-traded bonds on the Moscow Stock Exchange took place on December 24, 2020.
The issue volume amounted to 1 billion rubles, and the coupon rate was fixed at 9.5% per annum. The Group's production site, JSC Biochemik (MOEX: BIOH), acts as the guarantor for the release. The issuer's creditworthiness rating was assigned by the Expert RA rating agency at the ruBBB+ level with a stable outlook.